Protagenic Therapeutics Total Assets
Protagenic Therapeutics total assets. Based on the latest financial reports, Protagenic Therapeutics (PTIX) holds total assets worth $2.13 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Protagenic Therapeutics for the company's overall valuation and market capitalisation.
Total Assets of Protagenic Therapeutics (1995–2025)
Total assets of Protagenic Therapeutics from 1995 to 2025. This chart illustrates how Protagenic Therapeutics's total assets have evolved over time, based on quarterly financial data. See PTIX live share price for real-time trading data and today's change.
Protagenic Therapeutics - Asset Composition Analysis
Protagenic Therapeutics Total Assets Breakdown (December 2025)
Protagenic Therapeutics total assets breakdown as of December 2025. Protagenic Therapeutics's total assets of $2.13 Million consist of 107.8% current assets and -7.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 103.8% |
| Accounts Receivable | $41.52K | 2.0% |
| Inventory | $1.07K | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.09 Million | 98.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Protagenic Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PTIX net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Protagenic Therapeutics's current assets represent 107.8% of total assets in 2025, an increase from 46.9% in 1995.
- Cash Position: Cash and equivalents constituted 103.8% of total assets in 2025, up from 4.9% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 98.0% of total assets, an increase from 30.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 98.2% of total assets.
Protagenic Therapeutics Competitors by Total Assets
Key competitors of Protagenic Therapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Protagenic Therapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 2.00 | 0.30 |
| Quick Ratio | 0.34 | 2.00 | 0.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.52 Million | $940.11K | $-454.83K |
Protagenic Therapeutics - Advanced Valuation Insights
This section examines the relationship between Protagenic Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.35 |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | 9.0% |
| Total Assets | $2.13 Million |
| Market Capitalization | $1.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values Protagenic Therapeutics's assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Protagenic Therapeutics's assets grew by 9.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Protagenic Therapeutics (1995–2025)
The table below shows the annual total assets of Protagenic Therapeutics from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.13 Million | +9.01% |
| 2024-12-31 | $1.96 Million | -54.76% |
| 2023-12-31 | $4.32 Million | -46.21% |
| 2022-12-31 | $8.04 Million | -27.33% |
| 2021-12-31 | $11.06 Million | +1157.89% |
| 2020-12-31 | $879.25K | +4.39% |
| 2019-12-31 | $842.27K | +20.86% |
| 2018-12-31 | $696.88K | -60.87% |
| 2017-12-31 | $1.78 Million | -43.67% |
| 2016-12-31 | $3.16 Million | +2277.38% |
| 2015-12-31 | $133.00K | 0.00% |
| 2015-06-30 | $133.00K | -45.93% |
| 2014-12-31 | $246.00K | 0.00% |
| 2013-12-31 | $246.00K | -74.21% |
| 2012-12-31 | $954.00K | -95.07% |
| 2010-12-31 | $19.34 Million | -56.63% |
| 2009-12-31 | $44.60 Million | -43.38% |
| 2008-12-31 | $78.76 Million | +228.69% |
| 2007-12-31 | $23.96 Million | +336.17% |
| 2006-12-31 | $5.49 Million | -20.98% |
| 2004-12-31 | $6.95 Million | -49.40% |
| 2003-12-31 | $13.74 Million | -36.18% |
| 2002-12-31 | $21.53 Million | -7.49% |
| 2001-12-31 | $23.27 Million | +1.54% |
| 2000-12-31 | $22.92 Million | -0.05% |
| 1999-12-31 | $22.93 Million | +6.78% |
| 1998-12-31 | $21.48 Million | +36.19% |
| 1997-12-31 | $15.77 Million | +25.45% |
| 1996-12-31 | $12.57 Million | +13.45% |
| 1995-12-31 | $11.08 Million | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.